They may take my car. They may take my home. Aye, they may turn off my lights. But, they will never take my Netflix or my Spotify!
Emerging utilities? $NFLX $SPOT
“Momentum will always reorient to what’s trending, away from weakness, irrespective of style boxes.
That adaptability of momentum is why it has been one of the best performing factor premiums over time.
But there’s a jump you have to make from just getting momentum exposure, to getting positive outcomes… decisions like when and how to rebalance and risk management make a huge difference.
In short, momentum is very simple in theory, but difficult in practice.
That is where we come in...”
Learn more by tuning in to the @excessreturnpod where I join @practicalquant and @JJCarbonneau for a deep dive into all things momentum investing.
https://t.co/325p4otAsd
Skills to pay the bills! $ATGE $LAUR $LINC $UTI all have momentum as more seem to be ditching the traditional 4 year college experience. All hit new 52 wk highs this week.
Gen Z is building skills to pay the bills!
They are skipping the four-year college path, choosing “skilled collar” careers - healthcare, trades, technical fields - drawn by faster, cheaper training and clearer payoffs.
Momentum is building. Recent earnings from $UTI, $LINC and $ATGE show it’s not just a blip—it’s structural.
Policy shifts + rising demand = tailwind for career schools.
Follow for more Rising Tides - concise insights into some of the themes moving our portfolios.
https://t.co/PiLHzXCrJs
"There is tremendous opportunity even in these dislocated market environments."
Having a style of investing like momentum can help pick up on trends, no matter where they emanate.
Click below for the full segment on Yahoo Finance TV.
https://t.co/u6DMIvvs6I
K-Beauty is Back – and it’s Outselling France.
• South Korea just overtook France as the #1 exporter of cosmetics to the US, with imports topping $1.76B in 2023.
• Kolmar Korea and APR Corp are riding the wave - innovating with stick sunscreens, spicule delivery tech, and ultra-inclusive product lines.
• The next beauty export? “mirror skin” - a hyper-reflective look already catching on in US skincare aisles.
It's not just Korean skincare that has momentum. Follow along for more trends moving our portfolios.
https://t.co/XWWJJrz4nY
Nuclear’s heating up.
Nuclear stocks have surged following President Trump’s Executive Orders aimed at accelerating nuclear development.
$CEG estimates demand for nuclear power will increase by 167% over the next 5 years.
This means growth potential for newer nuclear technology adoption - particularly small modular reactors to power data centers, as evidenced by $SMR hitting a 52-week high.
Momentum is building across the board. US and South Korean nuclear equipment suppliers $GEV, $CW, nuclear power producers $NRG, and Korean nuclear plant construction companies (Doosan Enerbility) are all hitting 52-week highs.
More detail here:
https://t.co/buUJeGgUjN
The tariff tantrum and economic uncertainty have rattled US equity markets this year. From a factor perspective, it is beta and volatility that have driven returns.
Other styles and factors, including momentum, have been less important in the vacillation between risk off/risk on.
For perspective, the Russell 3000 Index has climbed 20% since the low on April 8th, with the highest quintile beta stocks up over 41% for the period!
https://t.co/OI28E62pTJ
Infrastructure, eh?
Canada is committing over $129B in infrastructure spending over four years, with dedicated funds for housing, transit, energy, defense, and Indigenous partnerships.
Add in a ‘buy-Canada’ bias for materials like steel and timber, and you’ve got a sustained, multi-sector buildout underway.
Canadian stocks exhibiting signs of momentum include beneficiaries like AtkinsRéalis (national transit projects), WSP, Stantec $STN (engineering megaprojects and grid design) and Finning International (construction equipment). Find this interesting?
Like or share, and follow along for more Rising Tides.
https://t.co/vU2nzAxDMO
Global pharma is knocking on China's door.
Multinational pharmaceutical companies are increasingly tapping into Chinese biotechs for innovative R&D. Over 30% of large pharma in-licensed drugs are now from China. The latest - $PFE licensing an oncology asset from 3SBio for up to $6B in milestones.
Why? China is R&D-advantaged. Clinical trials are 30-50% cheaper and faster with new policies in April 2025, cutting approval timelines to <20 weeks.
Further details, including stocks benefiting from this trend at the link below.
Like or share if you found this interesting.
https://t.co/riN0OS26EQ
~60% of Greek bank market cap is projected to be returned to shareholders by 2026.
Click the link below to find out what's driving the dramatic turnaround in the Greek banking sector.
https://t.co/qit9RHzbhb
$NVDA may be gaining momentum, but the bigger story is the broadening strength across the entire AI tech-industrial complex since early April.
Thanks @BrianSozzi for having me on @YahooFinance this morning. The market has indeed been a resilient basketcase this year – driven almost entirely by volatility and beta – but we’re seeing that dynamic shifting.
https://t.co/2rNVId68ZE
The AI and industrials trade has gained renewed traction, particularly in the US.
Tech giants have steadily been increasing their capital expenditure to enhance AI infrastructure, with a new focus on AI inference and robotics.
Stocks tied to data centers and AI compute like $ORCL, $NVDA, $MU, and $KLAC are seeing strong momentum. Even small caps like $STRL are breaking out.
Click the link below 👇 for our latest Rising Tide.
https://t.co/hKUkUSE5yH
"As stocks are hitting all-time highs, we're seeing new leadership emerge after what has been a really noisy and beta-driven market so far this year."
Thanks to @SchwabNetwork for having me on to cover where we’re seeing strong momentum from a global perspective.
https://t.co/4cfJXeK7cH
The global drone market is set to more than double by 2030, surging from $73B to $163B.
A big driver is a surge in defense spending, but it goes beyond that. Click below to find out more.
https://t.co/cTMqzg0kwl
@AlecStapp@Sam__Enright A harmful idea is one thing. But many books in this thread are simply books that were written in a way to be enjoyable or digestible by non-experts. And there's nothing wrong with that. Especially if your goal is to sell books.